Article

BCAN's First "Bladder Cancer Matters" Podcast is Now Available

In the inaugural “Bladder Cancer Matters” podcast, host Rick Bangs interviews Dr. Ashish Kamat about the state of BCG in bladder cancer treatment. Dr. Kamat is a Professor (Tenure) of Urology and Director of Urologic Oncology Fellowship at MD Anderson Cancer Center, and a graduate of the AUA Leadership Program. Dr. Kamat also serves on BCAN’s Scientific Advisory Board.

In the inaugural “Bladder Cancer Matters” podcast, host Rick Bangs interviews Dr. Ashish Kamat about the state of BCG in bladder cancer treatment. Dr. Kamat is a Professor (Tenure) of Urology and Director of Urologic Oncology Fellowship at MD Anderson Cancer Center, and a graduate of the AUA Leadership Program. Dr. Kamat also serves on BCAN’s Scientific Advisory Board.

In this episode, Rick and Dr. Kamat discuss what BCG is, how it is used, why there is a BCG shortage and what some therapeutic alternatives are.

This episode is sponsored by FerGene, a new gene therapy company dedicated to creating and delivering innovative solutions for bladder cancer.

Click on this link to listen to the fascinating 30 minute conversation: https://bcan.org/what-up-with-bladder-cancer-and-bcg-with-dr-ashish-kamat/

Related Videos
Image of a man with rectangular glasses and a goatee.
Woman with dark brown hair and pink lipstick wearing a light pink blouse with a light brown blazer. Patients should have conversations with their providers about treatments after receiving diagnoses.
Dr. Psutka in an interview with CURE
Dr. Sarah Psutka in an interview with CURE at the ASCO Annual Meeting
Kristie L. Kahl and Dr. Tracy L. Rose
Dr. Tracy Rose
Dr. Tracy L. Rose
Kristie L. Kahl and Tracy L. Rose
Related Content
Illustration of a bladder in blue.
November 22nd 2024

Initial Keytruda May Be Beneficial in Patients With Advanced Bladder Cancer

Spencer Feldman
Initial Keytruda showed consistent antitumor activity and safety in patients with advanced bladder cancer ineligible for platinum-based chemotherapy.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
FDA Approval Withdrawal of Trodelvy Leaves Fewer Bladder Cancer Options
November 6th 2024

FDA Approval Withdrawal of Trodelvy Leaves Fewer Bladder Cancer Options

Alex Biese
The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.
cancer horizons podcast logo
December 20th 2023

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

Alex Biese Brielle Benyon
The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
Tranexamic Acid During Radical Cystectomy Does Not Lead to Blood Transfusion Reduction in Bladder Cancer
October 24th 2024

Tranexamic Acid During Radical Cystectomy Does Not Lead to Blood Transfusion Reduction in Bladder Cancer

Ryan Scott
The use of prophylactic tranexamic acid didn't lead to a reduction in blood transfusion for patients undergoing open radical cystectomy for bladder cancer.
Image of doctor pointing at illustration of bladder.
October 22nd 2024

FDA Approval of Trodelvy Withdrawn for Urothelial Carcinoma

Darlene Dobkowski, MA
The withdrawal of the FDA accelerated approval for locally advanced or metastatic urothelial carcinoma, a type of bladder cancer, does not affect other indications of the therapy.